


Nivolumab CHECKMATE-76K

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Nivolumab CHECKMATE-76K

FINAL SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Skin Cancers  
Therapeutic Indication: Adjuvant treatment of completely resected Stage IIB/C melanoma in patients 12 years and older.  
Experimental Arm: Nivolumab  
Control Arm: Placebo

